Ever since CRISPR technology arrived, it has been refining its capabilities and tackling increasingly difficult problems—including problems of global scope

GEN Genetic Engineering & Biotechnology News, September 2022

Building programmable CRISPR platform, Spotlight aims at cancer targets with $36.5M series B

GV-backed, Bay Area biotech focusing on immuno-oncology for internal gene editing pipeline while mulling partnerships elsewhere

BioCentury, March 2022

Guided by biotech vet, East Bay gene editing startup raises $36.5M

With the idea to correct gene mutations to cure diseases, the company now has raised close to $70 million and could be in the clinic with its first therapeutic in 2024

San Francisco Business Times, March 2022

VENTURE INVESTMENT IN CRISPR GENE EDITING SPURS INNOVATION, HUNT FOR IP

Hayward, Calif.-based Spotlight Therapeutics Inc., focus on delivering gene-editing drugs more effectively to sites of disease in the body. Using cell-targeting proteins, for example, Spotlight potentially could deliver gene-editing enzymes into immune cells surrounding a tumor in an effort to treat cancer, said CEO Mary Haak-Frendscho.

The Wall Street Journal, March 2022

Spotlight Therapeutics’ cell-specific in vivo gene editing platform, TAGE, takes center stage

TAGE enables targeted gene editing in the tumor microenvironment to enhance immuno-oncology responses

Nature Biopharma Dealmakers Advertisement Feature, September 2021

Spotlight Therapeutics: making CRISPR deliver in vivo

Moving beyond viral vectors and lipid nanoparticles, Spotlight is conjugating Cas proteins to agents that will home endonucleases and their guide RNAs to targets in vivo

Nature Biotechnology news feature, July 2021

Gene Editing Startups Cut Fine Therapeutic Figures

New companies are exploiting next-generation CRISPR technologies and powerful CRISPR alternatives to realize new therapeutic approaches

Genetic Engineering and Biotechnology News, December 2020

Spotlight: solving CRISPR’s delivery challenges with RNPs

Emerging Company Profile: Spotlight developing tissue-targeted CRISPR therapies with $30M A round led by GV

BioCentury, December 2020